What about the study they need to conduct in the U
Post# of 85468
“This regulatory milestone is a major step towards the commercial launch in the U.S. and signifies our commitment to advancing patient care and safety through cutting-edge medical devices,” stated Ronnie Klein, IR-MED’s CTO and Interim CEO. “Following our successful usability studies for PressureSafe™ in Israel, we are expanding these studies into the U.S. and expect to commence with a major hospital network in 2024.”